Reply to comment by Normanno et al on ‘A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens’

Por de Castro, D G, Lopez-Rios, F
Publicado em 2012

Lung adenocarcinoma in the era of targeted therapies: histological classification, sample prioritization, and predictive biomarkers

Por Conde, E., Angulo, B., Izquierdo, E., Paz-Ares, L., Belda-Iniesta, C., Hidalgo, M., López-Ríos, F.
Publicado em 2013

Multidisciplinary consensus on optimising the detection of NTRK gene alterations in tumours

Por Garrido, P., Hladun, R., de Álava, E., Álvarez, R., Bautista, F., López-Ríos, F., Colomer, R., Rojo, F.
Publicado no Clin Transl Oncol (2021)

Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medi...

Por Garrido, P., Conde, E., de Castro, J., Gómez-Román, J. J., Felip, E., Pijuan, L., Isla, D., Sanz, J., Paz-Ares, L., López-Ríos, F.
Publicado no Clin Transl Oncol (2019)

A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens

Por Gonzalez de Castro, D, Angulo, B, Gomez, B, Mair, D, Martinez, R, Suarez-Gauthier, A, Shieh, F, Velez, M, Brophy, V H, Lawrence, H J, Lopez-Rios, F
Publicado em 2012

SAUL, a single-arm study of atezolizumab for chemotherapy-pretreated locally advanced or metastatic carcinoma of the urinary tract: outcomes by key baseline factors, PD-L1 expressi...

Por Bamias, A., Merseburger, A.S., Loriot, Y., James, N., Choy, E., Castellano, D., Lopez-Rios, F., Calabrò, F., Kramer, M., de Velasco, G., Zakopoulou, R., Tzannis, K., Sternberg, C.N.
Publicado no ESMO Open (2021)

Stromal disrupting effects of nab-paclitaxel in pancreatic cancer

Por Alvarez, R, Musteanu, M, Garcia-Garcia, E, Lopez-Casas, P P, Megias, D, Guerra, C, Muñoz, M, Quijano, Y, Cubillo, A, Rodriguez-Pascual, J, Plaza, C, de Vicente, E, Prados, S, Tabernero, S, Barbacid, M, Lopez-Rios, F, Hidalgo, M
Publicado em 2013

Reply: ‘Comments on Stromal disrupting effects of nab-paclitaxel in pancreatic cancer'

Por Alvarez, R, Musteanu, M, Garcia-Garcia, E, Lopez-Casas, P P, Megias, D, Guerra, C, Muñoz, M, Quijano, Y, Cubillo, A, Rodriguez-Pascual, J, Plaza, C, de Vicente, E, Prados, S, Tabernero, S, Barbacid, M, Lopez-Rios, F, Hidalgo, M
Publicado em 2014

Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain

Por Hidalgo, M., Álvarez, R., Gallego, J., Guillén-Ponce, C., Laquente, B., Macarulla, T., Muñoz, A., Salgado, M., Vera, R., Adeva, J., Alés, I., Arévalo, S., Blázquez, J., Calsina, A., Carmona, A., de Madaria, E., Díaz, R., Díez, L., Fernández, T., de Paredes, B. G., Gallardo, M. E., González, I., Hernando, O., Jiménez, P., López, A., López, C., López-Ríos, F., Martín, E., Martínez, J., Martínez, A., Montans, J., Pazo, R., Plaza, J. C., Peiró, I., Reina, J. J., Sanjuanbenito, A., Yaya, R., Carrato, Alfredo
Publicado no Clin Transl Oncol (2016)